As 2026 brings the first wave of Medicare drug price negotiations under the Inflation Reduction Act, the landscape for high-cost cardiovascular medications like Repatha (evolocumab) has shifted ...
Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...
Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My doctor has put ...
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a ...
By Deena Beasley April 30 (Reuters) - Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for ...
Moby Strategic Performance and Portfolio Evolution. Management characterizes 2026 as a 'springboard year' where rapid growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results